Glial fibrillary acidic protein expression after transient brain ischemia: evidence for a pharmacological modulation by almitrine-raubasine.
Pujol
J F
JF
Laboratoire de Neuropharmacologie Moléculaire CNRS-UCB UMR105, Faculté de Médecine A. Carrel, Lyon, France.
Ginovart
N
N
Debure
L
L
Rousset
C
C
Weissmann
D
D
D015765:Almitrine / Q000627:therapeutic use*; D000818:Animals; D002340:Carotid Artery Diseases / Q000188:drug therapy / Q000378:metabolism; D003250:Constriction; D004338:Drug Combinations; D005849:Gerbillinae; D005904:Glial Fibrillary Acidic Protein / Q000096:biosynthesis*; D006624:Hippocampus / Q000098:blood supply*; D002546:Ischemic Attack, Transient / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D046948:Secologanin Tryptamine Alkaloids; D015016:Yohimbine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D004338:Drug Combinations; D005904:Glial Fibrillary Acidic Protein; D046948:Secologanin Tryptamine Alkaloids; D015016:Yohimbine; C005709:raubasine; D015765:Almitrine